Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Decreases By 93.8%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 19,300 shares, a drop of 93.8% from the January 15th total of 311,700 shares. Currently, 1.3% of the company’s stock are short sold. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is presently 0.0 days.

Salarius Pharmaceuticals Stock Performance

SLRX stock traded down $0.05 during mid-day trading on Thursday, hitting $1.66. 70,337 shares of the company were exchanged, compared to its average volume of 4,392,980. Salarius Pharmaceuticals has a 1-year low of $1.22 and a 1-year high of $7.20. The firm’s 50 day simple moving average is $1.94 and its 200 day simple moving average is $1.78. The firm has a market cap of $2.62 million, a P/E ratio of -0.20 and a beta of 0.84.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.